Drug intelligence / Profile preview

NY-500

Development stage: Unknown
Lead developer: NAYA Biosciences
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

NY-500 is a bispecific antibody designed to function as both a PD-1 inhibitor and a VEGF inhibitor. This dual mechanism targets the programmed cell death protein 1 (PD-1) pathway, which plays a key role in immune checkpoint regulation, and vascular endothelial growth factor (VEGF), which is involved in angiogenesis. By inhibiting these two pathways, NY-500 aims to enhance anti-tumor immune responses while also disrupting tumor blood supply. The drug does not have an FDA designation at this time[1].

Targets

PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on NY-500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NY-500.

Explore the full profile